Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
LA JOLLA, Calif., Feb. 04, 2016 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at 2:15 p.m. ET (11:15 a.m. PT) on Thursday, February 11, 2016 at the 5th Annual Leerink Global Healthcare Conference in New York. The conference will be held at The Waldorf Astoria Hotel in New York City.
A live audio webcast and replay will be available in the Investors section of Kura Oncology's corporate website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura's pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor that is currently in three Phase 2 clinical studies: the first study in patients with locally advanced solid tumors that carry HRAS mutations; the second study in patients with peripheral T-cell lymphomas; and the third study, an investigator-sponsored Phase 2 trial, in patients with urothelial carcinoma tumors characterized by HRAS mutations. Kura’s preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL inhibitor program. For additional information about Kura Oncology, please visit www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849 5375 [email protected]
